SYMBICORT is a combination formulation containing budesonide, an inhaled corticosteroid (ICS), and formoterol, a long-acting beta 2 -adrenergic agonist bronchodilator (LABA), in a single inhaler.

The Food and Drug Administration (FDA) has approved Breztri Aerosphere ® (budesonide/glycopyrrolate/formoterol fumarate; BGF) for the maintenance treatment of asthma in adult and ...

The US Food and Drug Administration (FDA) on Wednesday said it approved new labeling for inhalers that combine long-acting beta agonists (LABAs) and inhaled corticosteroids (ICS) after reviewing ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

FDA considers this risk to be a class effect of all LABAs, including formoterol, one of the components of SYMBICORT. Currently available data are inadequate to determine whether concurrent use of ...

Among patients with mild asthma, as-needed use of a fixed-dose inhaler combining budesonide and formoterol (Symbicort) proved effective for preventing exacerbations and loss of lung function, but the ...

Please provide your email address to receive an email when new articles are posted on . Maintenance and reliever therapy using inhaled corticosteroids and formoterol was associated with lower risk for ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...

SYMBICORT is indicated for the treatment of asthma in patients 6 years and older not adequately controlled on a long-term asthma-control medication such as an ICS or whose disease warrants initiation ...